Discussion on prescribing ‘Dupixent’ to pediatric patients with atopic dermatitis is now showing visible progress.

According to industry sources, the National Health Insurance Service has started expert inquiries to start discussions on applying insurance benefits to the lower-dose (200mg) formulation of Sanofi-Aventis Korea’s Dupixent (dupilumab). This is 7 months since the company had applied for reimbursement in April. Accordingly, other processes including its deliberation date by the disease subcommittee, etc. are expected to be soon set.

The lower-dose Dupixent was approved in Korea in adolescent patients aged 12 or older with severe atopic dermatitis who are less than 60kg. Aft